EUVIMEDEUVIMED entdecken
Crossref

Demographic and clinical feature disparity between progress and non‐progress patients with vitiligo after COVID ‐19 vaccination: A cross‐sectional study

Xiaoyuan Hou, Nanhui Wu, Mingyuan Xu, Pramisha Kharel, Fei Wu, Yichen Wu, Ruiping Wang, Jia Chen iD

Experimental Dermatology · 2023

DOI: 10.1111/exd.14825 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Dermatology, 2023. Verfasst von Xiaoyuan Hou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatopathology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: COVID-19, Vitiligo. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There have been several case reports regarding newly developed vitiligo following the coronavirus disease 19 (COVID‐19) vaccination. However, the relationship between COVID‐19 vaccine and vitiligo progression remains unclear. To explore the relationship between COVID‐19 vaccine and vitiligo progression and its potential influencing factors, A cross‐sectional study was conducted on 90 patients with vitiligo who received inactivated COVID‐19 vaccination. Detailed information covering demographic characteristics (age and sex), vitiligo clinical features (disease subtypes, duration, stage and comorbidities) and disease activity was collected through an electronic questionnaire. Ninety patients with vitiligo included 44.4% males, with an average age of 38.1 years (standard deviation, SD = 15.0). Patients were divided into progress group (29, 32.2%) and normal group (61, 67.8%) based on whether they experienced vitiligo progression after inactivated COVID‐19 vaccination. 41.3% of patients in the progress group experienced vitiligo progression within 1 week after vaccination, and disease progression mainly occurred after the first dose inoculation (20, 69.0%). Logistic regression revealed that patients aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19VitiligoAdultAgedFemaleHumansMaleCOVID-19 VaccinesCross-Sectional StudiesDemographyVaccinationMiddle Aged

Stichwörter der Autor:innen

COVID-19autoimmunitydisease progressionvaccinationvitiligo

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Dermatopathology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
  • Clinical Research Center, Shanghai Skin Disease Hospital, Tongji University, Shanghai, China.
  • Department of Rheumatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.

ORCID-Profile: Jia Chen

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Hou, X., Wu, N., Xu, M., Kharel, P., Wu, F., Wu, Y., Wang, R., & Chen, J. (2023). Demographic and clinical feature disparity between progress and non‐progress patients with vitiligo after COVID ‐19 vaccination: A cross‐sectional study. Experimental Dermatology. https://doi.org/10.1111/exd.14825

Vancouver

Hou X, Wu N, Xu M, Kharel P, Wu F, Wu Y, et al. Demographic and clinical feature disparity between progress and non‐progress patients with vitiligo after COVID ‐19 vaccination: A cross‐sectional study. Experimental Dermatology. 2023. doi:10.1111/exd.14825

BibTeX
@article{Hou2023,
  author = {Hou, Xiaoyuan and Wu, Nanhui and Xu, Mingyuan and Kharel, Pramisha and Wu, Fei and Wu, Yichen and Wang, Ruiping and Chen, Jia},
  title = {Demographic and clinical feature disparity between progress and non‐progress patients with vitiligo after COVID ‐19 vaccination: A cross‐sectional study},
  journal = {Experimental Dermatology},
  year = {2023},
  doi = {10.1111/exd.14825}
}
Kostenlos starten →